Systematic literature review of real-world effectiveness results data for first-line ibrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma
P Lee, KD Kistler, L Douyon, R Volodarsky… - Drugs-Real World …, 2023 - Springer
Abstract Background and Objective Ibrutinib, an oral Bruton's tyrosine kinase inhibitor, has
demonstrated efficacy as a first-line treatment for chronic lymphocytic leukemia in multiple …
demonstrated efficacy as a first-line treatment for chronic lymphocytic leukemia in multiple …
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia
Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic
leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib …
leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib …
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
M Shadman, M Salkar, B Srivastava, S Karve… - Leukemia & …, 2024 - Taylor & Francis
This study used real-world data from three separate United States (US) databases to
evaluate dosing patterns and time to next treatment (TTNT) following the first-incident …
evaluate dosing patterns and time to next treatment (TTNT) following the first-incident …
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences
JC Barrientos, AO Ayed, A Cha, S Du, B Fang, R Hall… - Targeted Oncology, 2023 - Springer
Background Despite recent approvals of lifesaving treatments for chronic lymphocytic
leukemia (CLL), real-world data on the tolerability of the Bruton tyrosine kinase inhibitor …
leukemia (CLL), real-world data on the tolerability of the Bruton tyrosine kinase inhibitor …
[PDF][PDF] Inhibitors of Bruton's Tyrosine Kinase for Treating Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma
RZ Lin - cdn.mdedge.com
Background: Patients with high-risk chronic lymphocytic leukemia and/or small lymphocytic
leukemia (CLL and/or SLL) mount a poor response to conventional chemoimmunotherapy …
leukemia (CLL and/or SLL) mount a poor response to conventional chemoimmunotherapy …
[HTML][HTML] Highlights in Chronic Lymphocytic Leukemia From the 61st American Society of Hematology Annual Meeting and Exposition
FT Awan - hematologyandoncology.net
Ibrutinib is an oral Bruton tyrosine kinase (BTK) inhibitor that is approved for the treatment of
chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 1 Acalabrutinib is …
chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 1 Acalabrutinib is …